Abstract: Compounds and compositions useful in methods of treating genitourinary syndrome of menopause (GSM). These compounds, and compositions containing these compounds, may be used as an alternative to systemic hormonal therapies or to localized therapies using estradiol or other forms of steroidal estrogens.

Abstract: At least one compound chosen from compounds of Formula I: a pharmaceutically acceptable salt or ester thereof, a solvate thereof, a chelate thereof, a non-covalent complex thereof, a prodrug thereof, and mixtures of any of the foregoing, wherein: n is a number from 1 to 900, wherein the individual units may be the same or different; W is chosen from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; each of R2, R3, R4 and R5 is independently chosen from —H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; Z? is chosen from —O—, —N—, —NO—, —NR4—, —S—, —SO— and —SO2—, wherein R4 is defined as above; each of X, X?, Y and Z is independently chosen from —CR4R5—, —NH—, —NR4—, —NO—, —O—, —NOR4—, —S—, —SO—, —SO2—, wherein R4 and R5 are defined as above; R1 is chosen from a tocopherol, a steroid and a flavonoid; and R6 is chosen from any R1, alkyl, substituted alkyl, cycloalkyl

Abstract: This invention relates to methods and compositions for increasing the bioavailability of pharmaceutical or lipophilic compounds. The invention further relates of methods of administering the compounds and compositions of the present invention to a human or animal.

Abstract: Compounds and compositions are disclosed for increasing the bioavailability of lipophilic drugs, and more specifically, to solubilizing lipophilic drugs using bioenhancers that cause no efflux inhibition or a desired degree of efflux inhibition. Methods of making and using such compositions are also disclosed.